ArticleACS omega2026
CRISPR/Cas12a2-Mediated Ultrasensitive Assay for Rapid Detection of H1N1 Influenza Virus RNA.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The H1N1 influenza virus poses a major global public health challenge, highlighting an urgent demand for advanced diagnostic technologies that enable rapid and accurate detection. This study established a novel CRISPR-Cas12a2-based diagnostic platform for highly sensitive and rapid detection of influenza A H1N1 virus. Targeting the conserved M gene, the assay combined optimized crRNA design with the unique dual RNA cleavage and collateral ssDNA degradation activities of SuCas12a2, enabling fluorescence-based detection with a sensitivity of 5 copies/μL. Clinical validation of 205 nasopharyngeal swabs demonstrated 91.22% concordance with real-time qPCR (κ = 0.65) and identified 18 additional positive cases, indicating superior sensitivity. The assay achieved a detection limit of 5 RNA copies/μL within 90 min by combining through a reverse transcription PCR with CRISPR detection. Rigorous specificity testing confirmed 100% discrimination against other respiratory pathogens. These results positioned CRISPR-Cas12a2 as a robust diagnostic alternative, offering advantages in speed and sensitivity. This technology represents a significant advancement in molecular diagnostics, meeting the critical needs for rapid and accurate pathogen detection during outbreaks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.